Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 101

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 101
---
 in 2004, except for 2024 due to changes in fair value of convertible notes, warrant liability
and an approval received from the European Commission Executive Agency for Small and Medium-sized Enterprises, or EASME in 2024 which
resulted in a recognition of approximately $2 million research and development expense reduction. We incurred net income of $4.8 million
and a net loss of $4.1 million for the year ended December 31, 2024 and 2023, respectively, and $3.2 million net loss and $7.2 million
net income for the six months ended June 30, 2025 and 2024 respectively. As of June 30, 2025 and December 31, 2024, we had an accumulated
deficit of $45.3 million and $42.1 million, respectively. We anticipate that we will continue to incur significant losses for the
foreseeable future as our operating expenses and capital expenditures increase substantially due to our continued investment in our research
and development activities and as we hire additional employees over the coming years. Furthermore, upon closing of this offering, we
expect to incur additional expenses associated with operating as a public company on the NYSE American, including significant legal,
accounting, investor relations and other expenses.

For further information regarding
our business and operations, see “Business” below.

Components of Operating Results

Revenues

We have not recognized any
revenue to date, and we do not expect to generate revenue from the sale of products in the near future.

Research and Development Expenses

Research and development
activities are our primary focus. We do not believe that it is possible at this time to accurately project total expenses required for
us to reach the point at which we will be ready to out-license our technologies. Development timelines, the probability of success and
development costs can differ materially from expectations. In addition, we cannot forecast whether and when collaboration arrangements
will be entered into, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We
also received non-royalty bearing grant from the European Union through the European Commission Executive Agency for Small and Medium-sized
Enterprises as part of the Horizon 2020 Research and Innovative Framework Programme, or the Horizon 2020 Grant. The Horizon 2020 Grant
was fully recognized in the year ended December 31, 2024, as a reduction in research and development expense. We expect our research